Effect of portal vein ligation and silymarin treatment on aspirin metabolism and disposition in rats

Biopharmaceutics and Drug Disposition

Volumn 18, Issue 1, 1997, Pages 53-64

  Favari, Liliana ^a   Soto, Claudia ^a   Mourelle, Marisabel ^a  

^a Cinvestav IPN   (Mexico)

Author keywords

aspirin; metabolism; pharmacokinetics; portal hypertension; silymarin

Indexed keywords

ACETYLSALICYLIC ACID; CYTOCHROME P450; SILYMARIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PORTAL HYPERTENSION; PORTAL VEIN; RAT; VEIN LIGATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; ASPIRIN; CYTOCHROME P-450 ENZYME SYSTEM; HALF-LIFE; HYPERTENSION, PORTAL; LIGATION; LIVER; LIVER FUNCTION TESTS; MALE; PORTAL VEIN; RATS; RATS, WISTAR; SILYMARIN;

EID: 0031037062     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199701)18:1<53::AID-BDD3>3.0.CO;2-9     Document Type: Article

References (46)

1. G. R. Wilkinson, Influence of liver disease on pharmacokinetics. In Applied Pharmacokinetics, Principles of Therapeutic Drug Monitoring, Vol. 4, W. E. Evans, J. J. Schentag and W. T. Jusko (Eds), Applied Therapeutics, Spokane, WA, 1980, pp. 57-75.
2. R. L. Williams and L. Z. Benet, Drug pharmacokinetics in cardiac and hepatic disease. Annu. Rev. Pharmacol. Toxicol., 20, 389-413 (1980).
3. T. Blei, Pharmacokinetic-hemodynamic interactions in cirrhosis. Semin. Liver Dis., 6, 299-308 (1986).
4. J. C. Pector, S. Verbeustel and J. P. Lambilliote, Effect of portal arterialization on hepatic cytochrome P 450 in rats with portacaval shunts. Digestion, 12, 144-151 (1975).
5. E. Rubin, F. Hutterer, T. Ohshiro and J. H. Jacobson, Effect of experimental portacaval shunt on hepatic metabolizing enzymes. Proc. Soc. Exp. Biol. Med., 127, 444-447 (1968).
6. G. C. Farrell and L. Zaluzny, Portal vein ligation selectively lowers hepatic cytochrome P 450 levels in rats. Gastroenterology, 85, 275-282 (1983).
7. B. Ali and S. Kaur, Mammalian tissue acetylsalicylic acid esterases. Identification, distribution and discrimination from other esterases. J. Pharmacol. Exp. Ther., 226, 589-593 (1983).
8. A. Goldstein, L. Aronow and S. M. Kalman, In Principles of Drug Action: The Basis of Pharmacology, A. Goldstein, L. Aronow and S. M. Kalman (Eds), Wiley, New York, 1974. pp. 227-300.
9. P. Ferenci, B. Dragosics, H. Dittrich, H. Frank, L. Benda, H. Lochs, S. Meryn, W. Base and B. Schneider, Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J. Hepatol., 9, 105-113 (1989).
10. 4 induced liver cirrhosis by silymarin. Fundam. Clin. Pharmacol., 3, 183-191 (1989).
11. H. Schriever and H. M. Rauen, Die antihepatotoxische wirkung von parenteral verabreichtem Silymarin bei der Galaktosamin-hepatitis der ratte. Arzneim., Forsch. (Drug Res.), 23, 159-163 (1973).
12. G. A. Desplaces, J. Choppin, G. Vogel and W. Trost, The effects of silymarin on experimental phalloidin poisoning. Arzneim. Forsch. (Drug Res.), 25, 89-96 (1975).
13. P. Muriel, T. Garciapiña, V. Pérez-Alvarez and M. Mourelle, Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. J. Appl. Toxicol., 12, 439-442 (1992).
14. M. Chojkier and R. J. Groszmann, Measurement of portal-systemic shunting in the rat by using γ-labeled microspheres. Am. J. Physiol., 240, G371-G375 (1981).
15. P. Trinder, Rapid determination of salicylate in biological fluids. Biochem. J., 57, 301-303 (1954)
16. T. Omura and R. Sato, The carbon monoxide-binding pigment of liver microsomes. J. Biol. Chem., 239, 2370-2378 (1964).
17. P. Mazel. Experiments illustrating Drug Metabolism in vitro. In Fundamental of Drug Metabolism and Drug Disposition, B. N. La Du, H. G. Mandel and E. L. Way (Eds), Williams and Wilkins, Baltimore, MD, 1971, pp. 546-582.
18. J. G. Spenney, An ultraviolet absorbance method for determining acetylsalicylic acid hydrolase activity. Anal. Biochem., 80, 578-584 (1977).
19. M. M. Bradford, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 117, 248-254 (1976).
20. M. Gibaldi and D. Perrier, Pharmacokinetics, Dekker, New York, 1975, pp. 1-43.
21. M. Glossmann and G. N. Neville, Gamma-glutamyl transpeptidase in kidney brush border membranes. FEBS Lett., 19, 340-344 (1972).
22. L. Berger and G. N. Rudolph, Alkaline and acid phosphatase. In Standard Methods of Clinical Chemistry, Vol. 5, A. Meites (Ed.), Academic, New York, 1963, p. 56.
23. S. Reitman and S. Frankel, A colorimetric method for the determination of serum oxaloacetic and glutamic pyruvic transaminases. Am. J. Clin. Pathol., 28, 56 (1957).
24. R. J. Tallarida and R. B. Murray, Pharmacologic Calculations with Computer Programs, Springer, New York, 1981.
25. R. B. Groszmann, J. N. Kotelanski, R. Cohn and I. M. Khatri, Quantitation of porto-systemic shunting from the splenic and mesenteric beds in alcoholic liver disease. Am. J. Med., 53, 715-722 (1972).
26. K. Okuda, K. Suzuki, H. Masha and N. Arimizu, Percutaneous transhepatic catheterization of the portal vein for the study of portal hemodynamics and shunts. Gastroenterology, 73, 279-284 (1977).
27. D. H. Van Thiel, J. S. Galarer, F. L. Slone, C. F. Cobb, W. I. Smith Jr., K. M. Bron and R. Lester, Is feminization in alcoholic men due in part to portal hypertension?: a rat model. Gastroenterology, 78, 81-91 (1980).
28. J. C. Pector, S. Verbeustel and J. P. Lambilliote, Effect of portacaval shunt on hepatic cytochrome P 450 in rats. Rev. Eur. Etudes Clin. Biol., 17, 791-793 (1972).
29. J. C. Pector, F. W. Ossenberg, M. Peignoux and J. P. Benhamou, The effect of portacaval transposition on hepatic cytochrome P 450 in the rat. Biomedicine, 23, 160-162 (1975).
30. 4-induced chronic liver damage. Biochem. Pharmacol., 36, 3021-3025 (1987).
31. G. C. Farrell, A. Koltai, L. Zaluzny and M. Murray, Effects of portal vein ligation on sex hormone metabolism in male rats. Relationship to lowered hepatic cytochrome P 450 levels. Gastroenterology, 90, 299-305 (1986).
32. K. Krishnaswamy and A. N. Naidu, Microsomal enzymes in malnutrition as determined by plasma half life of antipyrine. Br. Med. J., 1, 538-540 (1977).
33. A. M. Hoyumpa, R. A. Branch and S. Schenker, The disposition and effects of sedatives and analgesics in liver disease. Annu. Rev. Med., 29, 205-218 (1978).
34. J. Caldwell, The significance of phase II (conjugation) reactions in drug disposition and toxicity. Life Sci., 24, 571-578 (1979).
35. M. Rowland, Effect of some physiologic factors on bioavailability of oral dosing forms. In Dosage Form Design and Bioavailability, J. Swarbrick (Ed.), Lea and Febiger, Philadelphia, PA, 1973, pp. 183-223.
36. G. Pomier-Layrargues, P. M. Huet, J. P. Villeneuve and D. Marleau, Effect of portacaval shunt on drug disposition in patients with cirrhosis. Gastroenterology, 91, 163-167 (1986).
37. K. Iwamoto, J. Watanabe, K. Aroki, M. Satoh and N. Deguchi, Reduced hepatic clearance of propranolol induced by chronic carbon tetrachloride treatment in rats. J. Pharmacol. Exp. Ther., 234, 470-475 (1985).
38. E. A. Neal, P. J. Meffin, P. B. Gregory and T. F. Blasckke. Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis. Gastroenterology, 77, 96-102 (1979).
39. P. A. Harris and S. Riegelman, Influence of the route of administration on the area under the plasma concentration-time curve. J. Pharm. Sci., 58, 71-75 (1969).
40. J. M. Krowss, P. V. Desmond, J. P. Marshall, R. F. Johnson, S. Schenker and G. R. Wilkinson, Effects of aging and liver disease on disposition of lorazepam. Clin. Pharmacol. Ther., 24, 411-419 (1978).
41. 4 liver damage. J. Appl. Toxicol., 10 (4), 275-279 (1990).
42. P. Muriel and M. Mourelle, The role of membrane composition in ATPase activities in cirrhotic rat liver: effect of silymarin. J. Appl. Toxicol., 10 (4), 281-284 (1990).
43. R. Meib, U. Heinrich, H. Robener and H. Themann, Effect of silybin on hepatic cell membranes after damage by polycyclic aromatic hydrocarbons (PAH). Agents Actions, 12 (1,2), 254-257 (1982).
44. W. H. Down, L. F. Chasseaud and R. K. Grundy, Effects of silybin on the hepatic microsomal drug-metabolizing enzyme system in the rat. Arzneim. Forsch. (Drug Res.), 24 (2), 1986-1988 (1974).
45. L. W. Wattenberg, M. A. Page and J. L. Leong, Induction of increased benzopyrene hydroxylase activity by flavones and related compounds. Cancer Res., 28, 934-937 (1968).
46. B. Havsteen, Flavonoids. A class of natural products of high pharmacological potency. Biochem. Pharmacol., 37, 1141-1148 (1983).